Cannula Market size was valued USD 190 million in 2024 and is anticipated to reach USD 342.3 million by 2032, at a CAGR of 7.64% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Cannula Market Size 2024
USD 190 million
Cannula Market, CAGR
7.64%
Cannula Market Size 2032
USD 342.3 million
Cannula Market Insights
Rising volumes of cardiopulmonary bypass and extracorporeal membrane oxygenation procedures are key growth drivers, with cardiopulmonary bypass applications accounting for an estimated ~55% share due to routine cardiac surgeries.
Ongoing trends include the adoption of biocompatible materials, thin-wall designs, and improved flow dynamics to enhance safety, reduce hemolysis, and support complex and long-duration procedures.
Competitive dynamics are shaped by continuous product innovation, strict regulatory compliance, clinician training programs, and long-term supply relationships with hospitals and cardiac centers.
Regionally, North America leads the global market with an exact 38% share, supported by advanced cardiovascular infrastructure, high procedure volumes, and strong reimbursement frameworks, while Asia-Pacific shows faster growth momentum.
Cannula Market Segmentation Analysis:
By Size
The cannula market by size shows clear differentiation driven by clinical indication, patient anatomy, and flow requirements. The 20–22 Fr segment dominates the size-based landscape, accounting for an estimated 26% market share, as it offers an optimal balance between adequate flow rates and reduced vascular trauma in adult cardiothoracic and extracorporeal procedures. Strong adoption is supported by its compatibility with standard cardiopulmonary bypass circuits and ECMO setups. Smaller sizes (14–19 Fr) maintain steady demand in pediatric and minimally invasive procedures, while larger sizes (26–36 Fr) are selectively used in high-flow, complex cardiac surgeries.
For instance, Freelife Medical GmbH engineers arterial and venous cannulae in the 20–22 Fr range with optimized tip geometry supporting flow rates above 5.5 liters per minute at clinically acceptable pressure gradients, reinforced thin-wall tubing with wall thickness below 0.6 millimeters, and laser-etched depth markers at 5-millimeter intervals to improve placement accuracy and procedural safety.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
By application, cardiopulmonary bypass (CPB) surgery represents the leading segment, holding approximately 48% of the total market share, supported by the high global volume of open-heart procedures. Cannulas used in CPB are optimized for stable high-flow perfusion, hemodynamic control, and reduced hemolysis, reinforcing their clinical preference. Extracorporeal membrane oxygenation (ECMO) follows as a fast-growing segment due to rising incidence of acute respiratory failure and cardiac shock. Other applications, including trauma and specialized vascular procedures, contribute incremental demand driven by procedural diversification.
For instance, Medtronic’s high-performance cannulas, such as the Bio-Medicus™ NextGen and EOPA™ (Elongated One-Piece Arterial) series, are engineered to support blood flow rates up to 7 liters per minute, providing sufficient perfusion for large adult patients during CPB and long-term ECLS.
By End User
In terms of end users, hospitals dominate the cannula market with an estimated 64% market share, reflecting their role as primary centers for complex cardiac surgeries, ECMO deployment, and critical care interventions. High procedural volumes, availability of specialized surgical teams, and access to advanced perfusion infrastructure sustain hospital dominance. Ambulatory surgical centers are gradually expanding adoption, particularly for less complex cardiovascular and minimally invasive procedures, supported by cost-efficiency initiatives. Other end users, including specialty clinics and research centers, account for a smaller but stable share driven by niche procedural requirements.
Key Growth Drivers
Rising Volume of Cardiovascular and Critical Care Procedures
The cannula market benefits directly from the growing number of cardiovascular surgeries, extracorporeal membrane oxygenation (ECMO) procedures, and critical care interventions worldwide. An aging population, increasing prevalence of cardiac disorders, and higher survival rates of complex surgeries continue to drive procedural volumes. Hospitals increasingly rely on high-performance cannulas that offer improved flow dynamics, reduced hemolysis, and enhanced patient safety. This sustained rise in procedure demand supports consistent procurement cycles and reinforces long-term market expansion across both adult and pediatric care settings.
For instance, Andocor’s high-performance adult cannulae, particularly the Flex Line and Venous series, are engineered and validated to sustain continuous blood flow exceeding 6 liters per minute.
Advancements in Cannula Design and Material Technologies
Continuous innovation in cannula design significantly accelerates market growth. Manufacturers focus on biocompatible materials, thin-wall constructions, kink-resistant shafts, and optimized tip geometries to improve clinical outcomes and ease of use. Enhanced coatings that reduce thrombogenicity and improve blood compatibility further increase adoption. These technological advancements enable clinicians to perform complex procedures with greater precision and reduced complication risks, strengthening physician confidence and driving replacement demand for advanced cannula systems across surgical and intensive care applications.
For instance, Getinge AB has developed arterial and venous cannulas using medical-grade polyurethane reinforced with embedded wire coils designed to maintain lumen integrity at bend radii below 25 millimeters, supports continuous flow performance above 6 liters per minute in cardiopulmonary bypass configurations, and applies biocompatible surface treatments validated through internal testing to significantly reduce platelet adhesion during extended blood-contact durations exceeding 6 hours.
Expansion of Healthcare Infrastructure in Emerging Economies
Rapid healthcare infrastructure development in emerging markets is a key growth driver for the cannula market. Governments and private healthcare providers are investing heavily in cardiac care units, advanced surgical centers, and critical care facilities. Improved access to specialized procedures increases the demand for essential consumables such as cannulas. Additionally, growing medical tourism and expanding reimbursement coverage in select regions further stimulate procurement volumes, supporting steady market growth beyond traditionally dominant developed healthcare systems.
Key Trends & Opportunities
Shift Toward Minimally Invasive and Percutaneous Procedures
A notable trend in the cannula market is the increasing preference for minimally invasive and percutaneous procedures. Clinicians seek cannulas that support smaller access points while maintaining optimal flow performance. This shift creates opportunities for manufacturers to develop low-profile, flexible cannulas designed for minimally invasive techniques. As hospitals aim to reduce patient trauma, shorten recovery times, and lower overall treatment costs, demand for specialized cannulas aligned with these procedural trends continues to rise.
For instance, BD (Becton Dickinson) has engineered the BD Venflon™ Pro Safety IV Cannula with BD Vialon™ polyurethane material that softens in-vein up to 70 percent to support longer dwell times and lower mechanical phlebitis risk, incorporates BD Instaflash™ needle technology for immediate visual confirmation of vessel entry, and offers catheter lengths such as a 22 gauge, 45 mm configuration delivering approximately 31 mL/min gravity flow while its passive safety shield fully encapsulates the needle tip upon withdrawal to reduce accidental needlestick exposures.
Growing Adoption of ECMO and Advanced Life Support Therapies
The expanding use of ECMO and advanced life support therapies presents a strong growth opportunity. Cannulas designed specifically for prolonged support, stable positioning, and high flow efficiency are increasingly required in intensive care units. Rising awareness of ECMO benefits in respiratory and cardiac failure cases encourages hospitals to strengthen their capabilities. This trend supports demand for premium cannula products with enhanced durability, secure fixation features, and compatibility with modern life support systems.
For instance, LivaNova plc has developed specialized cardiopulmonary cannulae such as the ProtekSolo™ arterial cannula available in sizes 15 Fr × 17 cm and 17 Fr × 17 cm with wire-reinforced tubing to preserve lumen integrity at extended lengths, and venous return cannulae like the dual-stage 32/40 Fr model with an effective length of 41 cm, designed to support consistent drainage performance in high-flow bypass circuits.
Increasing Focus on Pediatric and Neonatal Care Solutions
There is a growing emphasis on pediatric and neonatal cannula solutions as survival rates improve for critically ill infants and children. This creates opportunities for highly specialized, size-specific cannulas that minimize vascular trauma and support delicate physiological conditions. Manufacturers investing in precision-engineered pediatric portfolios can address this niche yet expanding segment, benefiting from higher clinical value perception and strong demand from specialized pediatric care centers.
Key Challenges
Stringent Regulatory Requirements and Compliance Burden
The cannula market faces challenges from stringent regulatory frameworks governing medical devices. Compliance with evolving quality standards, clinical validation requirements, and post-market surveillance obligations increases development timelines and costs. Smaller manufacturers may struggle to meet these requirements, limiting innovation speed. Delays in regulatory approvals can also slow product launches and restrict market entry, particularly in regions with complex approval pathways, thereby impacting overall market competitiveness.
Pricing Pressure and Hospital Cost Containment
Intensifying pricing pressure poses a significant challenge for cannula manufacturers. Hospitals and healthcare systems increasingly emphasize cost containment, often favoring bundled procurement and competitive tendering processes. This environment limits pricing flexibility, even for technologically advanced products. Manufacturers must balance innovation investments with cost efficiency while maintaining product quality. Sustained margin pressure may affect smaller players disproportionately and intensify competition, especially in high-volume, standardized cannula segments.
Regional Analysis
North America
North America leads the global cannula market with an estimated 38% market share, supported by high procedure volumes in cardiovascular surgery, ECMO, and critical care. Advanced healthcare infrastructure, widespread adoption of technologically advanced cannulas, and strong reimbursement frameworks drive consistent demand. Hospitals and specialized cardiac centers prioritize high-performance cannulas with improved flow efficiency and biocompatible materials, reinforcing premium product adoption. The strong presence of established manufacturers, continuous product innovation, and early uptake of advanced life-support technologies further strengthen North America’s dominant position in the global cannula market.
Europe
Europe accounts for approximately 28% of the global cannula market, driven by a well-established public healthcare system and rising prevalence of cardiovascular and respiratory diseases. Countries such as Germany, France, and the UK show strong demand due to increasing surgical volumes and expanding ECMO capabilities. Strict regulatory standards encourage the adoption of high-quality, clinically validated cannula products. Additionally, growing investments in hospital modernization and critical care infrastructure support steady replacement demand, positioning Europe as a mature yet innovation-driven regional market.
Asia-Pacific
Asia-Pacific represents around 22% market share and is the fastest-growing region in the cannula market. Rapid expansion of healthcare infrastructure, increasing access to advanced surgical procedures, and rising awareness of critical care therapies drive growth. Countries such as China, India, and Japan are witnessing higher cardiovascular disease incidence, leading to increased procedural volumes. Government initiatives to improve tertiary care facilities and growing medical tourism further stimulate demand. Cost-effective cannula offerings and rising adoption of advanced devices support strong regional growth momentum.
Latin America
Latin America holds an estimated 7% share of the global cannula market, supported by gradual improvements in healthcare access and increasing investments in cardiac and critical care services. Brazil and Mexico are key contributors due to expanding hospital networks and rising surgical procedure volumes. Although budget constraints limit rapid adoption of premium devices, demand for reliable and cost-effective cannulas remains strong. Ongoing public-private partnerships and incremental upgrades in critical care infrastructure are expected to support moderate but steady market growth.
Middle East & Africa
The Middle East & Africa region accounts for roughly 5% of the global cannula market, reflecting developing healthcare systems and uneven access to advanced procedures. Gulf countries drive regional demand through significant investments in advanced hospitals and cardiac care centers. In contrast, parts of Africa experience slower adoption due to limited infrastructure and funding constraints. However, increasing government healthcare spending, expansion of tertiary care facilities, and rising awareness of life-support therapies are gradually improving cannula demand across the region.
Cannula Market Segmentations:
By Size:
14-16 Fr
17-19 Fr
By Application:
Cardiopulmonary bypass surgery
Extracorporeal membrane oxygenation
By End User:
Hospitals
Ambulatory surgical centers
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Competitive Landscape
The cannula market players such as Freelife Medical GmbH, Medtronic, plc., Andocor, Nipro Corp., Surgical Holdings, Getinge AB, BD, LivaNova plc, Fresenius Medical Care. The cannula market is characterized by a moderately consolidated competitive environment in which manufacturers compete primarily on product reliability, clinical performance, and regulatory compliance. Market participants focus on advancing material quality, flow dynamics, and structural integrity to support demanding applications such as cardiopulmonary bypass and extracorporeal life support. Continuous design refinements, including thin-wall constructions, kink resistance, and atraumatic tip configurations, are widely adopted to enhance procedural safety and clinician control. Companies also emphasize manufacturing consistency, adherence to international quality standards, and comprehensive validation to secure long-term contracts with hospitals. In addition, strategic investments in R&D, expansion of global distribution networks, and alignment with evolving surgical protocols enable suppliers to maintain competitiveness while addressing rising procedure volumes and increasingly complex clinical requirements.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In May 2025, Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) approved YUTREPIA™ (treprostinil) inhalation powder, a dry powder prostacyclin analog, for adults with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) to improve exercise ability, marking a significant advancement for treating these rare cardiopulmonary conditions with an easy-to-use, deep-lung delivery device.
In September 2024, Shockwave Medical has expanded its U.S. peripheral intravascular lithotripsy (IVL) portfolio by introducing an enhanced catheter, designed for treating calcified arterial lesions.
In April 2024, The FDA has announced a recall of Arrow QuickFlash Radial Artery Catheterization Kits due to potential device malfunctions that could pose safety risks. This highlights the importance of stringent quality standards in arterial cannula manufacturing to ensure reliability and safety in procedures like arterial line placement and catheterization.
In March 2024, Merck, known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension. WINREVAIR is a breakthrough biologic for this rare, progressive disease.
Report Coverage
The research report offers an in-depth analysis based on Size,Application, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Growing volumes of cardiac and extracorporeal procedures will continue to drive steady demand for advanced cannula solutions.
Manufacturers will prioritize improved flow efficiency and reduced hemolysis to support complex and long-duration procedures.
Adoption of biocompatible and kink-resistant materials will accelerate to enhance patient safety and clinical outcomes.
Product designs will increasingly focus on ease of insertion and precise placement to support minimally invasive techniques.
Integration of cannulas with next-generation perfusion and ECMO systems will strengthen system-level compatibility.
Expanding aging populations will increase the need for cardiovascular and critical care interventions.
Regulatory emphasis on quality assurance will push manufacturers toward higher manufacturing and validation standards.
Emerging markets will offer growth opportunities through expanding surgical infrastructure and training programs.
Customization of cannula sizes and configurations will gain importance to address diverse patient anatomies.
Ongoing innovation and clinical collaboration will remain essential to sustain competitive positioning.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Cannula Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Size
6.1. 14–16 Fr
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. 17–19 Fr
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity 7. Market Breakup by Application
7.1. Cardiopulmonary Bypass Surgery
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Extracorporeal Membrane Oxygenation
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity 8. Market Breakup by End User
8.1. Hospitals
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Ambulatory Surgical Centers
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Freelife Medical GmbH
14.3.2. Medtronic plc
14.3.3. Andocor
14.3.4. Nipro Corp.
14.3.5. Surgical Holdings
14.3.6. Getinge AB
14.3.7. BD
14.3.8. LivaNova plc
14.3.9. Fresenius Medical Care
14.3.10. Edwards Lifesciences 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Cannula Market, and what is its projected size in 2032?
The cannula market was valued at USD 190 million in 2024 and is projected to reach USD 342.3 million by 2032.
At what Compound Annual Growth Rate is the Cannula Market projected to grow between 2024 and 2032?
The market is expected to grow at a CAGR of 7.64% during the forecast period from 2025 to 2032.
Which Cannula Market segment held the largest share in 2024?
The cardiopulmonary bypass application segment held the largest share, accounting for approximately 48% of the market in 2024.
What are the primary factors fueling the growth of the Cannula Market?
Key drivers include rising cardiovascular and ECMO procedures, advancements in cannula design and materials, and expanding healthcare infrastructure.
Who are the leading companies in the Cannula Market?
Leading players include Freelife Medical GmbH, Medtronic, plc., Andocor, Nipro Corp., Surgical Holdings, Getinge AB, BD, LivaNova plc, Fresenius Medical Care, and Edward Lifesciences.
Which region commanded the largest share of the Cannula Market in 2024?
North America dominated the market in 2024, accounting for an exact 38% share due to high procedure volumes and advanced healthcare infrastructure.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Dilated Cardiomyopathy Therapeutic Market size was estimated at USD 5,240.95 million in 2025 and is expected to reach USD 8,025.37 million by 2032, growing at a CAGR of 7.36% from 2025 to 2032.
The global Digital Pathology Image Analysis Market size was estimated at USD 3,425.85 million in 2025 and is expected to reach USD 7,503.83 million by 2032, growing at a CAGR of 13.96% from 2025 to 2032.
The Divalproex Sodium Market size was estimated at USD 1,860.58 million in 2025 and is expected to reach USD 2,453.73 million by 2032, growing at a CAGR of 4.72% from 2025 to 2032.
The global somatostatin analogs market was valued at USD 7,187.5 million in 2024 and is projected to reach USD 12,349.46 million by 2032, expanding at a compound annual growth rate (CAGR) of 7% during the forecast period.
The global respiratory disease vaccine market was valued at USD 94,579.5 million in 2024 and is projected to reach USD 102,011.14 million by 2032, expanding at a compound annual growth rate (CAGR) of 2.1% during the forecast period
The hepatic encephalopathy market was valued at USD 1432.5 million in 2024 and is expected to reach USD 2176.7 million by 2032, registering a CAGR of 5.4% during the forecast period.
The cardiac pacemakers market was valued at USD 5,298 million in 2024 and is expected to reach USD 7,702.9 million by 2032. The market is projected to grow at a CAGR of 4.79% during the forecast period.
The cancer immunotherapy drug discovery outsourcing market was valued at USD 1,432 million in 2024 and is expected to reach USD 2,981.48 million by 2032. The market is projected to grow at a CAGR of 9.6% during the forecast period.
The global healthcare cloud infrastructure market was valued at USD 76,788 million in 2024 and is projected to reach USD 260,555.1 million by 2032, expanding at a compound annual growth rate (CAGR) of 16.5% during the forecast period
The pregabalin market reached USD 1,794.5 million in 2024 and is projected to reach USD 2,631.16 million by 2032, growing at a CAGR of 4.9% during the forecast period. (Credence Research Data)
The Pregnancy Medication market was valued at USD 42,234.5 million in 2024 and is expected to reach USD 124,770.3 million by 2032, expanding at a CAGR of 14.5% during the forecast period.
The Germany guidewires market was valued at USD 151 million in 2024 and is projected to reach USD 229.68 million by 2032, registering a CAGR of 5.4% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
